Advicenne Informs About the Ongoing Safeguard Procedure

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today informs its shareholders that the hearing marking the end of the observation period under the safeguard proceedings will be held on November 9, 2026, before the Paris Commercial Court. Consequently, the Company will provide an update on the next steps in the safeguard proceedings upon receipt of the court’s decision following the hearing.

The observation period was initially scheduled to end on November 5, 2026, with the possibility of extension for an additional six months.

About Advicenne

Advicenne (Euronext Growth Paris ALDVI - FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal Renal Tubular Acidosis (dRTA) in EU, the UK, KSA and UAE, and is marketed in more than twenty-five countries in Europe. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: https://advicenne.com/.

Disclaimer

This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2025 Universal Registration Document filed with the French financial market authority on April 24, 2026 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or currently not considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103115852/en/

Advicenne
Didier Laurens, CEO
+33 (0)1 87 44 40 17
Email: [email protected]

Ulysse Communication
Media relations
Bruno Arabian
+33 (0)6 87 88 47 26
Email: [email protected]

Source: Advicenne

You May Also Be Interested In

• ICAPE - Q3 2026 Revenue of €68.7 Million: +36.4% Year-on-year and +34.2% Organically at Constant Exchange Rates
• American Fusion(TM) Inc. (AMFN) Reports Four Texatron(TM) Commercial Proposals as Pulsed-Power Testing Advances
• Standard Premium Finance Holdings, Inc. Brings Its Disciplined Growth Plan to Institutional and Accredited Investors at the PIPEs Conference